Effect of exercise versus control group on cardiac inflammatory factors in patients with liver disease
Not Applicable
Recruiting
- Conditions
- iver disease.Liver disorders in diseases classified elsewhere
- Registration Number
- IRCT20120215009014N444
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Age 18 to 65 years
Liver failure
Exclusion Criteria
Diabetes, asthma or cardiovascular diseases
Using tobacco, drugs, alcohol, or stimulants
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac inflammatory factors. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: By laboratory tests.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link exercise to reduced cardiac inflammation in liver disease patients?
How does exercise compare to standard care in managing cardiac inflammatory factors in liver disorders?
Which biomarkers correlate with exercise-induced improvements in cardiac inflammation for liver disease?
What adverse events are associated with exercise interventions in patients with liver disease?
Are there combination therapies that enhance exercise effects on cardiac inflammation in liver disease?